International Clinical Trials in Nephrology/Urology
Argentina
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bahia Blanca; Hospital Italiano Regional del Sur - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Belén de Escobar; Grupo Plaza - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Capital Federal, Buenos Aires; Instituto Quirúrgico del Callao - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Capital Federal, Buenos Aires; Instituto Alexander Fleming - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Capital Federal, Buenos Aires; Hospital Italiano de Buenos Aires - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Concepción del Uruguay, Entre Ríos; Centro Oncológico LALCEC - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Córdoba; Hospital Italiano de Cordoba - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Mendoza; COIR - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Rosario; CAICI - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Rosario; Centro Oncológico Rosario - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
San Miguel de Tucumán, Tucumán; Centro San Roque - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Santa Fe; Clinical Especializada ISIS
Belgium
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bruxelles; AZ-VUB - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bruxelles; Hopital Erasme - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bruxelles; UCLC St Luc - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bruxelles; Institut Jules Bordet - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Bruxelles; University Hospital Erasme - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Various Cities; Az Groeninge, Kortrijk
Canada
- Organ Transplant: A Randomized, Open-Label, Comparative Evaluation Of Conversion From Calcineurin Inhibitor Treatment To Sirolimus (Rapamune) Treatment versus Continued Calcineurin Inhibitor Treatment In Liver Allograft Recipients Undergoing Maintenance Therapy
Edmonton, Alberta; University of Alberta Hospital - Organ Transplant: A Randomized, Open-Label, Comparative Evaluation Of Conversion From Calcineurin Inhibitor Treatment To Sirolimus (Rapamune) Treatment versus Continued Calcineurin Inhibitor Treatment In Liver Allograft Recipients Undergoing Maintenance Therapy
London, Ontario; London Health Sciences Center, University Campus - Organ Transplant: A Randomized, Open-Label, Comparative Evaluation Of Conversion From Calcineurin Inhibitor Treatment To Sirolimus (Rapamune) Treatment versus Continued Calcineurin Inhibitor Treatment In Liver Allograft Recipients Undergoing Maintenance Therapy
Toronto, Ontario; Toronto General Hospital - Prostate Cancer: Randomized phase II study of irofulven regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer whose disease has progressed following Taxotere ® treatment.
Calgary; Research Site - Prostate Cancer: Randomized phase II study of irofulven regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer whose disease has progressed following Taxotere ® treatment.
Vancouver; Research Site - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
London; London Regional Cancer Centre - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Montreal; Centre Hospitalier de L'Universite de Montreal - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
North Fleurimont; Centre Hospitalier Universitaire Sherbrooke - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Winnepeg; Medical Oncology Cancercare Manitoba - Renal Cell Carcinoma: A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Cote du Palais, Quebec; Chug-L'Hotel - Renal Cell Carcinoma: A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Edmonton, Alberta; Cross Cancer Institute - Renal Cell Carcinoma: A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Halifax, Nova Scotia; Nova Scotia Cancer Centre Canc - Renal Cell Carcinoma: A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Hamilton, Ontario; St. Joseph's Health Care Centre - Renal Cell Carcinoma: A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Newmarket; Community Cancer Clinic - Renal Cell Carcinoma: A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Vancouver, British Columbia; Vancouver General Hospital
Europe
- Prostate Cancer: Randomized phase II study of irofulven regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer whose disease has progressed following Taxotere ® treatment.
Various Countries/Cities; Research Site
France
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bordeaux Cedex; Institut Bergoni?/br> - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Dijon Cedex; Centre Georges François Leclerc - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
La Roche Sur Yon; Centre Hospitalier Départemental - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Le Kremlin Bicetre; CHU de Bicêtre - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Lyon; CRLC Léon Bérard - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Montpellier Cedex 5; CRLC Val d'Aurelle Paul-Lamarque - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Paris; Hôpital Tenon - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Poitiers Cedex; CHU de Poitiers - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Reims; Institut Jean , Service d'Oncologie - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Tours; Hôpital le Bretonneau - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Vandoeuvre Les Nancy; Centre Alexis Vautrin
Hungary
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Budapest; St. Istvan Hospital - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Budapest; National Institute of Oncology - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Budapest; St. Margit Hospital - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Pecs; Pecs Medical University - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Vac; Javorszky Odon Hospital - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Budapest; Korolyi Sandor Hospital - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Miskolc; Borsod County Teaching Hospital
Israel
- Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Ashkelon; Barzilai Medical Centre - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Petach Tikva; Rabin Medical Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Tel Aviv; Tel Aviv Sourasky Medical Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Tel Hashomer; Sheba Medical Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Zerifin; Assaf Harofe Medical Center
Italy
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Genoa; Istituto Nazionale per la Ricerca sul Cancro (IST) - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Rome; A.O. San Camillo-Forlanini
Peru
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Jesus Maria; ESSALUD
Poland
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Katowice; Szpital. Im. Emila Michalowskiego Oddzial Urologii - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Lodz; Akademia Medyczna w Lodzi Klinika Chemioterapii - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Lublin; Akademia Medyczna w Lublinie Klinika Urologii - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Szczecin; Akademia Medyczna w Szczecinie Klinika Urologii - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Warszawa; Wojskowy Instytut Medyczny Klinika Onkologii - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Siedlcach; Wojewodzki Szpital Specjalistyczny W
Russia
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Moscow; N.N. Blokchin Cancer Research Centre - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Obninsk, Kaluga Region; Medical Radiological Research Centre of Rams - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Saint Petersburg; Petrov Research Institute of Oncology - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
St Petersburg; City Hospital #2 - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
St Petersburg; St. Petersburg City Clinical Oncological Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Arkhangelsk; Arkhangelsk Regional Oncology Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Chelyabinsk; Chelyabinsk Regional Oncology Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Kazan; Kazan City Oncology Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Moscow; Blokhin Cancer Research Center Development - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Moscow; Russian Research Center of Radiology - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Moscow; Blokhin Cancer Research Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Moscow; Semashko Central Clinical Hospital - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Obninsk; Medical Rediological Research Centre of Ran - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Saint Petersburg; City Clinical Oncology Dispensary - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Samara; Samara Regional Oncology Center - Prostate Cancer: Study Of MEDI-522 In Combination With Docetaxel ± Low-Dose Estramustine And Zoledronic Acid In The Treatment Of Patients With Androgen-Independent Prostate Cancer That Has Metastasized To Bone.
Voronezh; Voronezh Regional Oncology Clinical Center
South America
- Prostate Cancer: Randomized phase II study of irofulven regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer whose disease has progressed following Taxotere ® treatment.
Various Countries/Cities; Research Site
United Kingdom
- Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Birmingham; CRUK Institute for Cancer Studies - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Bristol; Bristol Oncology Centre - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
London; Guy's hospital - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
London; St Bartholomew's Hospital - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Newcastle Upon Tyne; Northern Centre for Cancer Treatment - Prostate Cancer: SPARC Trial - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with One Cytotoxic Chemotherapy Regimen.
Sutton; Royal Marsden Hospital
Back to CWWorld
